Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-Amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl) -(S)ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034). Comparison across sensitive and resistant human tumor cell lines

Biochemical Pharmacology

Volumn 57, Issue 5, 1999, Pages 567-577

  Faessel, H élène M ^a   Slocum, Harry K ^a   Rustum, Youcef M ^a   Greco, William R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antifolate; Dihydrofolate reductase; Folic acid; Isobol; Polyglutamylation

Indexed keywords

4 [2 (2 AMINO 4 OXO 4,6,7,8 TETRAHYDRO 3H PYRIMIDINO[5,4,6] [1,4]THIAZIN 6 YL)ETHYL] 2,5 THIENOYLAMINOGLUTAMIC ACID; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; RHODAMINE B; TRANSFERASE INHIBITOR; TRIMETREXATE; UNCLASSIFIED DRUG;

ARTICLE; CECUM CARCINOMA; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; KINETICS; LUNG NEOPLASMS; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PYRIMIDINES; TRIMETREXATE; TUMOR CELLS, CULTURED;

EID: 0033104229     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00315-3     Document Type: Article

References (53)

1. Jackson R.C., Harkrader R.J. The contributions of de novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. Tattersall M.H.N., Fox R.M. Nucleosides and Cancer Treatment. 1981;18-31 Academic Press, Sydney.
2. Ahmed N.K., Haggitt R.C., Welch A.D. Enzymes of salvage and de novo pathways of synthesis of pyrimidine nucleotides in human colorectal adenocarcinomas. Biochem Pharmacol. 31:1982;2485-2488.
3. Denton J.E., Lui M.S., Aoki T., Sebolt J., Takeda E., Eble J.N., Glover J.L., Weber G. Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res. 42:1982;1176-1183.
4. Boritzki T.J., Bartlett C.A., Zhang C., Howland E.F., Margosiak S.A., Palmer C.L., Romines W.H., Jackson R.C. AG2034: A novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs. 14:1996;295-303.
5. Worzella J.F., Self T.D., Theobald K.S., Rutherford P.G., Gossett L.S., Shih C., Mendelsohn L.G. Antitumor therapeutic index of LY309887 is improved with increased folic acid supplementation in mice maintained on a folate deficient diet. Proc Am Assoc Cancer Res. 37:1996;2617.
6. Mendelsohn L.G., Shih C., Schultz R.M., Worzella J.F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and Lometrexol. Invest New Drugs. 14:1996;287-294.
7. Kisliuk R.L., Gaumont Y., Kumar P., Coutts M., Nair M.G., Nanavati N.T., Kalman T.I. The effect of polyglutamylation on the inhibitory activity of folate analogs. Goldman I.D. Proceedings of the Second Workshop on Folyl and Antifolyl Polyglutamates. 1985;319-328 Praeger, New York.
8. Kisliuk R.L., Gaumont Y., Powers J.F., Thorndike J., Nair M.G., Piper J.R. Synergistic growth inhibition by combination of antifolates. Picciano M.F., Stokstad E.L.R., Gregory J.F. III. Evaluation of Folate Metabolism in Health and Disease. 1990;79-89 Alan R. Liss, New York.
9. 10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res. 47:1987;5256-5260.
10. Galivan J., Nimec Z., Rhee M., Boschelli D., Oronsky A.L., Kerwar S.S. Antifolate drug interactions: Enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. Cancer Res. 48:1988;2421-2425.
11. Gaumont Y., Kisliuk R.L., Embey R., Piper J.R., Nair M.G. Folate enhancement of antifolate synergism in human lymphoma cells. Curtius H.C., Blau N., Ghisla S. Chemistry and Biology of Pteridines. 1990;1132-1136 W. de Gruyter, Berlin.
12. Faessel H.M., Slocum H.K., Jackson R.C., Boritzki T.J., Rustum Y.M., Nair M.G., Greco W.R. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation. Cancer Res. 58:1998;3036-3050.
13. Gaumont Y., Kisliuk R.L., Parsons J.C., Greco W.R. Quantitation of folic acid enhancement of antifolate synergism. Cancer Res. 25:1992;2228-2235.
14. Greco W.R., Park H.S., Rustum Y.M. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res. 50:1990;5318-5327.
15. Greco W.R., Bravo G., Parsons J.C. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev. 47:1995;331-385.
16. Tompkins W.A., Watrach A., Schmale J., Schultz R., Harris J. Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst. 52:1974;117-133.
17. Giard D.J., Aaronson S.A., Todaro G.J., Kersey J.H., Dosik H., Parks W.P. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 51:1973;1417-1423.
18. Rangan S.R.S. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer. 29:1972;117-121.
19. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J. Jr, Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
20. Lu K., Yin M., McGuire J.J., Bonmassar E., Rustum Y.M. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem Pharmacol. 50:1995;391-398.
21. Dolnick B.J., Lu K., Yin M., Rustum Y.M. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells. Adv Enzyme Regul. 37:1997;95-109.
22. Berger S.H., Jenh C., Johnson L.F., Berger F.G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol. 28:1985;461-467.
23. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 82:1990;1113-1118.
24. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
25. Priest D.G., Doig M.T. Tissue folate polyglutamate chain-length determination by electrophoresis as thymidylate synthase-fluorodeoxyuridylate ternary complexes. Methods Enzymol. 122:1986;313-319.
26. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
27. Levasseur L., Faessel H., Slocum H.K., Greco W.R. Precision and pattern in 96-well plate cell growth experiments. Proc Am Stat Assoc (Biopharm Section). 1995;227-232.
28. Greco W.R., Unkelbach H.D., Pöch G., Sühnel J., Kundi M., Bödeker W. Consensus on concepts and terminology for interaction assessment The Saaresilkä Agreement . Arch Complex Environ Studies. 4:1992;65-69.
29. Gessner P.K. The isobolographic method applied to drug interactions. Morselli P.L., Garattini S., Cohen S.N. Drug Interactions. 1974;349-362 Raven Press, New York.
30. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
31. Kane M.A., Waxman S. Biology of disease: Role of folate binding proteins in folate metabolism. Lab Invest. 60:1989;737-746.
32. 2. Cancer Res. 49:1989;6019-6023.
33. Takemura Y., Gibson W., Kimbell R., Kobayashi H., Miyachi H., Jackman A.L. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. J Cancer Res Clin Oncol. 122:1996;109-117.
34. Kano Y., Ohnuma T., Holland J.F. Folate requirements of methotrexate-resistant human acute lymphoblastic leukemia cell lines. Blood. 68:1986;586-591.
35. Ohnoshi T., Ohnuma T., Takahashi I., Scanlon K., Kamen B.A., Holland J.F. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res. 42:1982;1655-1660.
36. Sirotnak F.M., Moccio D.M., Goutas L.J., Kelleher L.E., Montgomery J.A. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res. 42:1982;924-928.
37. van der Veer L.J., Westerhof G.R., Rijksen G., Schornagel J.H., Jansen G. Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake. Leuk Res. 13:1989;981-987.
38. McGuire J.J., Heitzman K.J., Haile W.H., Russell C.A., McCloskey D.E., Piper J.R. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. Leukemia. 7:1993;1996-2003.
39. Lu K., Faessel H.M., Slocum H.K., Greco W.R., Rustum Y.M. Role of intracellular reduced folate pools on cellular sensitivity to trimetrexate (TMQ) and methotrexate (MTX) in a folypolyglutamate synthetase (FPGS)-deficient HCT-8 subline. Proc Am Assoc Cancer Res. 38:1997;1087.
40. van Der Laan B.F.A.M., Jansen G., Kathmann G.A.M., Westerhof G.R., Schornagel J.H., Hordijk G.J. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int J Cancer. 51:1992;909-914.
41. Galivan J., Rhee M.S., Johnson T.B., Dilwith R., Nair M.G., Bunni M., Priest D.G. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase. J Biol Chem. 264:1989;10685-10692.
42. Lu K., McGuire J.J., Slocum H.K., Rustum Y.M. Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells. Biochem Pharmacol. 53:1997;689-696.
43. Jansen G., Schornagel J.H., Kathmann I., Westerhof G.R., Hordijk G.J., van der Laan B.F.A.M. Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res. 4:1992;299-305.
44. Braakhuis B.J.M., Jansen G., Noordhuis P., Kegel A., Peters G.J. Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol. 46:1993;2155-2161.
45. Pizzorno G., Chang Y.M., McGuire J.J., Bertino J.R. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 49:1989;5275-5280.
46. van der Wilt C.L., Cloos J., de Jong M., Pinedo H.M., Peters G.J. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res. 7:1995;317-321.
47. Mendelsohn L.G., Gates S.B., Habeck L.L., Shakelford K.A., Worzalla J., Shih C., Grindey G.B. The role of dietary folate in modulation of folate receptor expression, folypolyglutamate synthetase activity and the efficacy and toxicity of Lometrexol. Adv Enzyme Regul. 36:1996;365-381.
48. Priest D.G., Doig M.T., Mangum M. Response of mouse hepatoma cell methylenetetrahydrofolate polyglutamates to folate deprivation. Biochim Biophys Acta. 756:1983;253-257.
49. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm. 45:1989;263-335.
50. Kisliuk R.L. Pteroylpolyglutamates. Mol Cell Biochem. 39:1981;331-345.
51. McGuire J.J., Bertino J.R. Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem. 38:(Spec No(Pt 1)):1981;19-48.
52. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Mol Pharmacol. 48:1995;459-471.
53. Gates S.B., Mendelsohn L.G., Shackelford K.A., Habeck L.L., Kursar J.D., Gossett L.S., Worzella J.F., Shih C., Grindey G.B. Characterization of folate receptor from normal and neoplastic murine tissue: Influence of dietary folate on folate receptor expression. Clin Cancer Res. 2:1996;1135-1141.